Jushi Holdings Inc. (“Jushi” or the
“Company”) (CSE: JUSH) (OTCQB: JUSHF), a globally focused,
multi-state cannabis and hemp operator, today announced its
financial results for the second quarter ended June 30, 2020.
All financial information is provided in U.S. dollars unless
otherwise indicated.
Second Quarter 2020 Financial Highlights
- Total revenue increased 73 percent sequentially to $14.9
million
- Gross profit of $7.5 million, an increase of 80 percent
sequentially
- Net loss of $9.3 million
- Adjusted EBITDA1 (Loss) of $(1.2) million, a $4.8 million
improvement as compared to the first quarter of 2020
- $50.8 million of cash and securities on the balance sheet as of
June 30, 2020
- Annualized revenue run-rate for July 2020 of approximately $89
million, an approximate 80 percent increase over the March
annualized run rate.2
Operational Highlights
- Closed equity acquisition of Pennsylvania grower-processor
permit holder
- Announced debt financing of an additional US$33.31 million as a
result of strong demand from new and existing shareholders and
Jushi management
- Opened 9th and 10th BEYOND/HELLO retail locations
- Announced the closing of the acquisition of Agape Total Health
Care Inc, a Pennsylvania medical marijuana dispensary permit
holder
- Launched adult-use sales at its Normal, IL dispensary
- Relaunched Beyond-Hello.com, providing "live" menus and
real-time access to store inventory
Management Commentary
“We’re thrilled with the ongoing performance of
our operations in Pennsylvania and Illinois, which drove our strong
sequential quarterly revenue growth of 73%,” said Jim Cacioppo,
Chairman and Chief Executive Officer of Jushi. “As we move into the
second half of the year, we’re focused on maintaining this momentum
by continuing to build depth in the markets where we operate today,
while thoughtfully driving operational improvements across our
footprint. With the recent closing of our Pennsylvania
grower-processor permit holder acquisition, we are looking forward
to supplying our BEYOND/HELLOTM stores, along with other licensed
retailers in the Commonwealth, with high-quality and competitively
priced cannabis products, including our award-winning brands ‘The
Lab’ and ‘The Bank’. Moreover, with ten BEYOND/HELLO dispensaries
now open, and several stores under development, we remain well
positioned to continue exceed patient needs as well as drive value
for our shareholders.”
Financial
Results for the Second Quarter Ended June 30,
2020 |
($ in thousands,
except per share amounts) |
|
|
|
|
|
Quarter EndedJune 30, 2020 |
Quarter EndedMarch 31, 2020 |
% change |
Revenue |
$ |
14,932 |
|
$ |
8,633 |
|
73 |
% |
Gross profit |
$ |
7,472 |
|
$ |
4,159 |
|
80 |
% |
Net (loss) income |
$ |
(9,308 |
) |
$ |
(15,898 |
) |
41 |
% |
Net (loss) income per share – basic |
$ |
(0.10 |
) |
$ |
(0.17 |
) |
41 |
% |
Net (loss) income per share – diluted |
$ |
(0.10 |
) |
$ |
(0.17 |
) |
41 |
% |
Adjusted EBITDA (loss) |
$ |
(1,213 |
) |
$ |
(5,959 |
) |
80 |
% |
Revenue in the second quarter of 2020 ("Q2
2020") increased 73 percent to $14.9 million, compared to $8.6
million in the first quarter of 2020 (“Q1 2020”). The 73 percent
increase in revenue was driven by Jushi’s acquisition of two
medical marijuana dispensaries in Illinois, one of which began
serving adult-use customers in March and the other in May, strong
organic revenue growth at the Company’s BEYOND/HELLO stores in
Pennsylvania, and successful procurement of product in these two
supply constrained markets.
Gross profit in Q2 2020 was $7.5 million,
resulting in a gross margin of 50 percent, compared to $4.2 million
with a gross margin of 48 percent in Q1 2020. The $3.3 million, or
80 percent increase in gross profit over the prior quarter was
primarily due to an increase in adult-use sales, improved product
mix, improved purchasing practices and more disciplined promotional
offers.
Q2 2020 net loss was $9.3 million, or $0.10 per
diluted share, compared to a net loss of $15.9 million, or $0.17
per diluted share, in Q1 2020. The $6.6 million reduction of net
loss in the second quarter was driven primarily by both higher
revenue and gross profit. In addition, the Company recorded a $2.3
million gain on investments and financial assets as a result of
improved market conditions, as well as an offsetting $3.7 million
fair value loss on derivative warrants issued in connection with
the debt offering that was announced in December 2019 and June
2020.
Adjusted EBITDA (Loss) in Q2 2020 was ($1.2)
million, compared to $(6.0) million in Q1 2020. Adjusted EBITDA
margins have continued to steadily improve during the quarter
through the combination of higher gross margins, reduced operating
expenses and improved store revenue performance.
Balance Sheet and Liquidity
As of June 30, 2020, the Company had $38.5
million of cash, as well as $12.3 million in short-term
investments. Total current assets of $62.4 million and current
liabilities of $34.4 million as of June 30, 2020. Net working
capital at the end of June 30, 2020 was $28.0 million. As of July
31, 2020, the Company had $46.7 million in cash and $8.7 million in
short-term investments, and is fully funded for the build-out of
the current portfolio. In August, the Company received the
remaining $4 million on its latest oversubscribed debt financing
round for a total of $33.31 million. Additionally, the Company
raised approximately $5 million from sale leasebacks that were
completed in the second quarter and early third quarter for a total
funds raised of approximately $38 million.
Operations Update
Pennsylvania:
In August 2020, Jushi announced the closing of its
equity acquisition of a Pennsylvania Grower-Processor permit
holder. The acquisition adds a 90,000 sq. ft. cannabis cultivation
and processing facility that is strategically located within
minutes of Interstate 81, Interstate 84 and the Pennsylvania
Turnpike, enabling efficient wholesale distribution to the 89
dispensaries currently open across the Commonwealth, including the
Company’s eight operational BEYOND/HELLO dispensaries in
Pennsylvania.
Since closing the acquisition, the Company’s focus has shifted
to optimizing the facility to ensure long term growth and market
share expansion in the Pennsylvania market. Jushi will be targeting
a series of operations and facility improvements combined with the
recently completed expansion of the facility. These improvements
are expected to significantly increase production of both
pre-packaged flower and extracted products. It is expected that the
operational improvements and expanded footprint, combined with the
introduction of new extraction technologies, increased facility
automation and utilization, and improved yields, will be
implemented over the next 12 to 15 months.
In June, the Company acquired 80% of the
economic and voting interests of Agape Total Health Care, Inc, a
Pennsylvania dispensary permittee, which takes the Company’s
subsidiary-held dispensary authorizations in Pennsylvania from 12
to 15.
Jushi opened two new dispensaries in Ardmore and
Reading, bringing its total store count in the Commonwealth to
eight medical dispensaries operating under the BEYOND/HELLO brand.
The Company has the right to operate up to 15 dispensaries and
expects to open the remaining seven locations within the next
twelve months. The Company also has an assignable purchase option
to acquire 100 percent of the equity of Pennsylvania Dispensary
Solutions (“PADS”), a Pennsylvania medical marijuana dispensary
permittee in the Commonwealth’s Northeast region. PADS currently
operates two medical marijuana dispensaries, with the right to
operate one additional dispensary in the region. The option expires
in February 2022, and the exercise is subject to certain closing
conditions, including approvals from all applicable regulatory
authorities.
As of August 1, 2020, the Company’s BEYOND/HELLO
Center City and Northern Liberties stores were reopened after being
compromised earlier this summer amid demonstrations in the city. To
date, the Company has recovered approximately $0.4 million in
damages from insurance proceeds.
Second quarter 2020 organic same-store revenue
in Pennsylvania increased approximately 50 percent as compared to
the first quarter of 2020, excluding the two temporarily closed
Philadelphia stores. This improved performance is due to improved
management and the relaunch of BEYOND-HELLO.com. In the second
quarter the Company also hired a head of retail operations in
Pennsylvania with significant retail experience in the Pennsylvania
retail market.
Illinois:
In February 2020, Jushi became the 100 percent
owner of two Illinois medical cannabis dispensaries located in
Sauget (adjacent to East St. Louis) and Normal (Bloomington-Normal
metro area). Since acquiring the two dispensaries, both locations
have been re-branded to BEYOND/HELLO and have begun adult-use
sales. The Sauget dispensary began adult-use sales in March 2020,
and the Normal dispensary began adult-use sales in May 2020. Each
dispensary is also eligible to seek approval from the Illinois
Department of Financial & Professional Regulation (“IDFPR”) to
open a second retail location, and such second retail locations are
currently undergoing regulatory approvals. Jushi plans to exercise
both options and has secured locations for both stores, with design
and construction in process. The Company expects to have all four
adult-use stores operating by the end of 2020 or by early first
quarter 2021.
Second quarter 2020 organic same store revenue
in Illinois increased approximately 330 percent from the first
quarter of 2020, driven by the introduction of adult-use sales, the
relaunch of BEYOND-HELLO.com, improved procurement, additional
store hours, and an improved in-store customer
experience.
Virginia:
In August 2020, Jushi’s majority owned Dalitso
LLC, a Virginia-based pharmaceutical processor for medical cannabis
extracts received approval from the Virginia Board of Pharmacy to
commence vertically integrated operations for the cultivation,
manufacture, and sale of medical cannabis. Dalitso is one of only
five applications to have received conditional approval for a
pharmaceutical processor permit issued by the Virginia Board of
Pharmacy, and one of only four to have received final approval and
permit issuance. The Company is in the final stages of completing
the build-out of its cultivation, manufacturing and retail facility
in Prince William County near the City of Manassas and expects the
facility to be operational in the late summer/early fall of
2020.
The Company anticipates adding five BEYOND/HELLO
branded medical dispensaries to Dalitso’s operations in Virginia.
These five BEYOND/HELLO branded medical dispensaries will be in
addition to the Dalitso’s pharmaceutical processor facility near
the City of Manassas, which will allow Dalitso to cultivate,
process, dispense and deliver medical cannabis to registered
patients in Virginia.
California:
In July 2020, Jushi acquired GSG SBCA,
Inc., a licensed Santa Barbara dispensary expected
to open in late September/ early October 2020. The city of
Santa Barbara is a limited license market and currently only allows
for three dispensaries to operate in the jurisdiction. The Company
also signed a $3.2 million sale-leaseback agreement related to the
real estate previously purchased in connection with this license.
The Company also intends to move forward in the merit-based
application process as one of only three selected applicants for a
storefront retail (and ancillary delivery) permit in Culver City,
California.
The Company will continue to pursue additional
retail opportunities in specific limited license markets in
California, particularly in jurisdictions with high barriers of
entry, limited market participants, and a firm handle on the local
unregulated market.
Preliminary Base Shelf Prospectus
Filing
The Company also announced today that it has
filed a preliminary short form base shelf prospectus (the “Shelf
Prospectus”) with the Securities Commissions in each of the
provinces of Canada (except Quebec).
The Shelf Prospectus, when made final, will
allow the Company to offer up to C$200 million subscription
receipts, debt securities, convertible securities, warrants,
subordinate voting shares, and units (together, “Securities”), or
any combination thereof, from time to time during the 25-month
period that the (final) Shelf Prospectus is effective. The Company
filed the Shelf Prospectus in order to maintain financial
flexibility, including for responding to significant regulatory
improvements and pursuing opportunistic acquisitions. The Company
has not entered into any agreements or arrangements to authorize or
offer any Securities pursuant to the Shelf Prospectus, nor has any
current process in place to issue Securities pursuant to any future
(final) Shelf Prospectus. The specific terms of any future offering
of Securities under the Shelf Prospectus, including the use of
proceeds from any offering, will be established in a prospectus
supplement to the Shelf Prospectus, which supplement will be filed
with the applicable Canadian securities regulatory authorities.
The Shelf Prospectus can be found under the
Company’s profile on SEDAR at www.sedar.com.
This news release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of the Securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
Financial Outlook
Mr. Cacioppo commented, “As a result of the
strong first half results and our expectation for continued strong
operating results in the second half of the year, we are providing
third quarter revenue guidance of $22 to $25 million and expect
third quarter Adjusted EBITDA to be close to breakeven. We are
reaffirming our fourth quarter 2020 revenues guidance of
approximately $25 and $30 million and expect fourth quarter
Adjusted EBITDA to be positive. Jushi is also reaffirming its 2021
revenue guidance of $200 to $250 million and is providing 2021
Adjusted EBITDA guidance of approximately $40 to $50 million.”
The Company’s MD&A and consolidated
financial statements for the second quarter June 30, 2020, along
with all previous public filings of the Company, may be found on
SEDAR at www.SEDAR.com.
1 Adjusted EBITDA, which is a non-IFRS measure,
excludes certain items which are detailed and reconciled to the
most comparable IFRS-reported measure in the attached
“Reconciliation of Non-IFRS Measures.”2 July 2020 revenue run-rate
adjusted for Philadelphia, PA store closures
Conference Call and Webcast
InformationManagement will host a conference call and
audio webcast on Thursday, August 27th at 9:00 a.m. ET to answer
questions about the Company's operational and financial highlights.
The dial-in numbers for the conference call are +1-877-407-0792
(U.S. Toll-Free) or +1-201-689-8263 (International). Please dial in
10 to 15 minutes prior to the start time of the conference call and
an operator will register your name and organization.
The conference call will also be available via
webcast, which can be accessed through the Investor Relations
section of Jushi's website, http://ir.jushico.com/.
For interested individuals unable to join the
conference call, an audio webcast replay will be available and can
be accessed on Jushi’s Investor Relations site,
http://ir.jushico.com/.
About Jushi Holdings
Inc. We are a globally focused cannabis and hemp
company led by an industry leading management team. In the United
States Jushi is focused on building a multi-state portfolio of
branded cannabis and hemp-derived assets through opportunistic
acquisitions, distressed workouts, and competitive applications.
Jushi strives to maximize shareholder value while delivering high
quality products across all levels of the cannabis and hemp
ecosystem. For more information please
visit www.jushico.com or our social
media channels, Instagram, Facebook, Twitter, and LinkedIn.
Non-IFRS Financial Measures
EBITDA and Adjusted
EBITDA are financial measures that are not
defined under IFRS. We define EBITDA as net income (loss), or
“earnings”, before interest, income taxes, depreciation, and
amortization. We define Adjusted EBITDA as EBITDA before: (i) fair
value adjustments on biological assets and fair value adjustments
on sale of inventory; (ii) share-based compensation expense; (iii)
fair value changes in derivative warrants; (iv) net gain on
business combination; (v) gains and losses on investments and
financial assets; and (vi) pre-acquisition expense.
We believe Adjusted EBITDA is a useful measure
to assess the performance of the Company as it provides more
meaningful operating results by excluding the effects of expenses
that are not reflective of our operating business performance and
other one-time or non- recurring expenses, and also provide
additional perspective and insights when analyzing the core
operating performance of the business. These supplemental non-IFRS
financial measures should not be considered superior to, as a
substitute for or as an alternative to, and should only be
considered in conjunction with, the IFRS financial measures
presented herein.
Jushi includes a store in the same-store base if
the store is operational for two consecutive full quarters. A store
is not included in same-store sales if it is closed for one week or
longer, such as for business interruption, remodeling, during the
stated period. Same-store sales growth is primarily a result of
changes in the number of customer transactions and changes in the
average transaction size. Jushi’s same-store sales growth is
primarily impacted by the expansion of its brand awareness,
continued menu innovation and the use technology. Jushi’s
same-store sales growth is also impacted by external factors
including the macro-economic environment that could affect consumer
spending.
Forward-Looking Information and
Statements
This press release contains certain
"forward-looking information" within the meaning of applicable
Canadian securities legislation and may also contain statements
that may constitute "forward-looking statements" within the meaning
of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such forward-looking
information and forward-looking statements are not representative
of historical facts or information or current conditions but
instead represent only the Company’s beliefs regarding future
events, plans or objectives, many of which, by their nature, are
inherently uncertain and outside of the Company’s control.
Generally, such forward-looking information or forward-looking
statements can be identified by the use of forward-looking
terminology such as “plans,” “expects” or “does not expect,” “is
expected,” “budget,” “scheduled,” “estimates,” “forecasts,”
“intends,” “anticipates” or “does not anticipate,” or “believes,”
or variations of such words and phrases or may contain statements
that certain actions, events or results “may,” “could,” “would,”
“might” or “will be taken,” “will continue,” “will occur” or “will
be achieved”. The forward-looking information and forward-looking
statements contained herein may include but are not limited to,
information concerning the expectations regarding Jushi, or the
ability of Jushi to successfully achieve business objectives, and
expectations for other economic, business, and/or competitive
factors.
By identifying such information and statements
in this manner, the Company is alerting the reader that such
information and statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
information and statements. In addition, in connection with the
forward-looking information and forward-looking statements
contained in this press release, the Company has made certain
assumptions. Among the key factors that could cause actual results
to differ materially from those projected in the forward-looking
information and statements are the following: the ability of Jushi
to successfully achieve business objectives, including with
regulatory bodies, employees, suppliers, customers and competitors;
changes in general economic, business and political conditions,
including changes in the financial markets; changes in applicable
laws; and compliance with extensive government regulation, as well
as other risks and uncertainties which are more fully described in
the Company’s Management, Discussion and Analysis for the three
months ended June 30, 2020, and other filings with securities and
regulatory authorities which are available at www.sedar.com.
Should one or more of these risks, uncertainties or other factors
materialize, or should assumptions underlying the forward-looking
information or statements prove incorrect, actual results may vary
materially from those described herein as intended, planned,
anticipated, believed, estimated or expected.
Although the Company believes that the
assumptions and factors used in preparing, and the expectations
contained in, the forward-looking information and statements are
reasonable, undue reliance should not be placed on such information
and statements, and no assurance or guarantee can be given that
such forward-looking information and statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such information and
statements. The forward-looking information and forward-looking
statements contained in this press release are made as of the date
of this press release, and the Company does not undertake to update
any forward-looking information and/or forward-looking statements
that are contained or referenced herein, except in accordance with
applicable securities laws. All subsequent written and oral
forward-looking information and statements attributable to the
Company or persons acting on its behalf is expressly qualified in
its entirety by this notice.
For further information, please contact:
Investor Relations Michael Perlman Executive
Vice President of Investor Relations and
TreasuryInvestors@jushico.com(561) 453-1308
Media ContactEllen MellodyMATTIO
CommunicationsEllen@Mattio.com (570) 209-2947
|
JUSHI HOLDINGS INC. AND SUBSIDIAIRIES |
CONDENSED UNAUDITED INTERIM CONSOLIDATED STATEMENTS OF
OPERATIONS AND COMPREHENSIVE INCOME (LOSS) |
(in thousands of U.S. dollars, except share and per share
amounts) |
|
|
|
|
|
Three Months Ended |
Three Months Ended |
Three Months Ended |
|
June 30, 2020 |
March 31, 2020 |
June 30, 2019 |
|
(unaudited) |
(unaudited) |
(unaudited) |
|
|
|
|
Revenue |
$ |
14,932 |
|
|
$ |
8,633 |
|
|
$ |
226 |
|
Cost of goods sold |
|
(7,495 |
) |
|
|
4,547 |
|
|
|
(12 |
) |
Gross profit before fair value adjustments |
$ |
7,437 |
|
|
$ |
4,086 |
|
|
$ |
214 |
|
Fair value adjustment on sale of inventory |
|
(33 |
) |
|
|
(127 |
) |
|
|
- |
|
Fair value adjustment on biological assets |
|
68 |
|
|
|
200 |
|
|
|
- |
|
Gross profit |
$ |
7,472 |
|
|
$ |
4,159 |
|
|
$ |
214 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
General and administrative expenses |
$ |
3,757 |
|
|
$ |
3,746 |
|
|
$ |
3,357 |
|
Salaries, wages and employee related expenses |
|
4,994 |
|
|
|
5,087 |
|
|
|
4,404 |
|
Share-based compensation expense |
|
1,211 |
|
|
|
1,319 |
|
|
|
1,530 |
|
Acquisition and deal costs |
|
159 |
|
|
|
485 |
|
|
|
943 |
|
Depreciation and amortization expense |
|
1,064 |
|
|
|
1,016 |
|
|
|
267 |
|
Total operating expenses |
$ |
11,185 |
|
|
$ |
11,653 |
|
|
$ |
10,501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations before other (expense) income |
$ |
(3,713 |
) |
|
$ |
(7,494 |
) |
|
$ |
(10,287 |
) |
|
|
|
|
Other (expense) income: |
|
|
|
Interest income |
$ |
38 |
|
|
$ |
77 |
|
|
$ |
53 |
|
Fair value changes in derivative warrants |
|
(3,748 |
) |
|
|
2,587 |
|
|
|
- |
|
Interest expense and finance charges |
|
(3,435 |
) |
|
|
(2,952 |
) |
|
|
(89 |
) |
Net gain on business combination |
|
- |
|
|
|
2,202 |
|
|
|
- |
|
Gains (losses) on investments and financial assets |
|
2,332 |
|
|
|
(8,210 |
) |
|
|
12 |
|
Listing expense |
|
- |
|
|
|
- |
|
|
|
(1,360 |
) |
Other expense, net |
|
235 |
|
|
|
(760 |
) |
|
|
(172 |
) |
Total other income (expense) |
$ |
(4,578 |
) |
|
$ |
(7,056 |
) |
|
$ |
(1,556 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss and comprehensive loss before tax |
$ |
(8,291 |
) |
|
$ |
(14,550 |
) |
|
$ |
(11,843 |
) |
Income tax expense |
|
(1,017 |
) |
|
|
(1,348 |
) |
|
|
- |
|
Net loss and comprehensive loss after tax |
$ |
(9,308 |
) |
|
$ |
(15,898 |
) |
|
$ |
(11,843 |
) |
Net loss attributable to non-controlling interests |
|
(429 |
) |
|
|
(281 |
) |
|
|
- |
|
Net loss and comprehensive loss attributable to Jushi shareholders
- basic and diluted |
$ |
(8,879 |
) |
|
$ |
(15,617 |
) |
|
$ |
(11,843 |
) |
Loss and comprehensive loss per share - basic and diluted |
$ |
(0.10 |
) |
|
$ |
(0.17 |
) |
|
$ |
(0.17 |
) |
Weighted average shares outstanding - basic and diluted |
|
92,264,221 |
|
|
|
93,317,981 |
|
|
|
69,920,489 |
|
|
|
|
|
|
|
|
|
|
|
|
|
JUSHI HOLDINGS INC. AND SUBSIDIAIRIES |
CONDENSED UNAUDITED INTERIM CONSOLIDATED STATEMENTS
OF FINANCIAL POSITION |
(in thousands of U.S. dollars) |
|
|
|
|
|
June 30, 2020 |
|
December 31, 2019 |
|
|
|
|
ASSETS |
|
|
|
CURRENT ASSETS: |
|
|
|
Cash and cash equivalents |
$ |
38,510 |
|
|
$ |
38,936 |
|
Investments in securities |
|
12,287 |
|
|
|
12,267 |
|
Other short-term financial assets |
|
- |
|
|
|
5,646 |
|
Accounts receivable |
|
55 |
|
|
|
395 |
|
Prepaid expenses |
|
4,669 |
|
|
|
2,565 |
|
Other current assets |
|
167 |
|
|
|
188 |
|
Inventory |
|
4,129 |
|
|
|
1,958 |
|
Biological assets |
|
359 |
|
|
|
271 |
|
Deferred acquisition costs |
|
2,250 |
|
|
|
2,320 |
|
Total current assets |
$ |
62,426 |
|
|
$ |
64,546 |
|
|
|
|
|
NON-CURRENT ASSETS: |
|
|
|
Property, plant and equipment |
|
42,593 |
|
|
|
22,592 |
|
Other long-term assets |
|
842 |
|
|
|
1,181 |
|
Other intangible assets, net |
|
105,061 |
|
|
|
93,686 |
|
Goodwill, net |
|
28,055 |
|
|
|
28,055 |
|
Total long-term assets |
$ |
176,551 |
|
|
$ |
145,514 |
|
Total assets |
$ |
238,977 |
|
|
$ |
210,060 |
|
|
|
|
|
LIABILITIES AND EQUITY |
|
|
|
CURRENT LIABILITIES: |
|
|
|
Accounts payable |
$ |
3,940 |
|
|
$ |
1,182 |
|
Accrued expenses and other current liabilities |
|
15,634 |
|
|
|
7,691 |
|
Short-term promissory notes payable |
|
13,107 |
|
|
|
15,635 |
|
Short-term lease obligations |
|
1,706 |
|
|
|
969 |
|
Short-term redemption liability |
|
- |
|
|
|
8,440 |
|
Total current liabilities |
$ |
34,387 |
|
|
$ |
33,917 |
|
|
|
|
|
LONG-TERM LIABILITIES: |
|
|
|
Other liabilities |
$ |
- |
|
|
$ |
2 |
|
Long-term promissory notes payable |
|
4,918 |
|
|
|
9,988 |
|
Senior notes |
|
41,930 |
|
|
|
10,736 |
|
Derivative warrants liability |
|
23,709 |
|
|
|
5,529 |
|
Long-term lease obligations |
|
14,352 |
|
|
|
5,529 |
|
Deferred tax liabilities |
|
19,978 |
|
|
|
20,334 |
|
Total liabilities |
$ |
139,274 |
|
|
$ |
86,035 |
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES |
|
|
|
|
|
|
|
EQUITY: |
|
|
|
Share capital and share reserves |
$ |
160,363 |
|
|
$ |
163,032 |
|
Accumulated deficit |
|
(73,163 |
) |
|
|
(48,667 |
) |
Total Jushi shareholders' equity |
$ |
87,200 |
|
|
$ |
114,365 |
|
Non-controlling interests |
|
12,503 |
|
|
|
9,660 |
|
Total equity |
$ |
99,703 |
|
|
$ |
124,025 |
|
Total liabilities and equity |
$ |
238,977 |
|
|
$ |
210,060 |
|
|
|
|
|
JUSHI HOLDINGS INC. AND SUBSIDIARIES |
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH
FLOWS |
(in thousands of U.S. dollars) |
|
|
|
|
|
Six Months EndedJune 30, 2020 |
|
Six Months EndedJune 30, 2019 |
|
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
Net loss |
$ |
(25,206 |
) |
|
$ |
(17,798 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
Depreciation and amortization, include amounts in costs of goods
sold |
|
2,139 |
|
|
|
413 |
|
Share-based payments |
|
2,530 |
|
|
|
1,931 |
|
Fair value changes in derivative warrants |
|
1,161 |
|
|
|
- |
|
Net gain on business combination |
|
(2,202 |
) |
|
|
- |
|
Losses (gains) on investments and financial assets |
|
5,878 |
|
|
|
(20 |
) |
Finance charge on lease liabilities |
|
829 |
|
|
|
73 |
|
Other non-cash interest expense |
|
2,497 |
|
|
|
131 |
|
Deferred income taxes |
|
(3,247 |
) |
|
|
- |
|
Fair value adjustments on sale of inventory and on biological
assets |
|
(108 |
) |
|
|
- |
|
Non-cash listing expense |
|
- |
|
|
|
1,361 |
|
Non-cash other expense, net |
|
525 |
|
|
|
172 |
|
Changes in operating assets and liabilities, net of
acquisitions: |
|
|
|
Accounts receivable |
$ |
340 |
|
|
$ |
325 |
|
Prepaid expenses and other current assets |
|
(1,917 |
) |
|
|
(1,450 |
) |
Inventory and biological assets |
|
(2,051 |
) |
|
|
(1,323 |
) |
Other long-term assets |
|
338 |
|
|
|
(109 |
) |
Accounts payable and accrued expenses |
|
8,085 |
|
|
|
2,288 |
|
Other long-term liabilities |
|
- |
|
|
|
(83 |
) |
Net cash flows used in operating activities |
$ |
(10,409 |
) |
|
$ |
(14,089 |
) |
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
Payments for acquisitions, net of cash acquired |
$ |
(7,577 |
) |
|
$ |
(4,115 |
) |
Payments for deferred acquisition costs |
|
- |
|
|
|
(8,499 |
) |
Purchases of property, plant and equipment |
|
(9,804 |
) |
|
|
(4,596 |
) |
Payments for investments in securities, net |
|
(4,354 |
) |
|
|
- |
|
Proceeds from financial asset |
|
5,193 |
|
|
|
- |
|
Net cash flows used in investing activities |
$ |
(16,542 |
) |
|
$ |
(17,210 |
) |
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
Issuance of shares for cash, net |
$ |
- |
|
|
$ |
79,519 |
|
Proceeds from exercise of share-based compensation |
|
- |
|
|
|
569 |
|
Proceeds from issuance of 10% Senior Notes and derivative warrants,
net of financing costs |
|
32,967 |
|
|
|
- |
|
Principal and financing costs on promissory notes payable |
|
(7,658 |
) |
|
|
- |
|
Payments on lease obligations |
|
(764 |
) |
|
|
(168 |
) |
Contribution from non-controlling interests |
|
1,993 |
|
|
|
- |
|
Net cash flows provided by financing activities |
$ |
26,538 |
|
|
$ |
79,920 |
|
|
|
|
|
Effect of currency translation on cash |
|
(13 |
) |
|
|
- |
|
|
|
|
|
NET CHANGE IN CASH |
$ |
(426 |
) |
|
$ |
48,621 |
|
|
|
|
|
CASH, BEGINNING OF PERIOD |
|
38,936 |
|
|
|
38,114 |
|
|
|
|
|
CASH, END OF PERIOD |
$ |
38,510 |
|
|
$ |
86,735 |
|
|
JUSHI HOLDINGS INC. AND SUBSIDIAIRIES |
Unaudited Reconciliation of Net Loss to Adjusted
EBITDA |
(in thousands of U.S. dollars) |
|
|
|
|
|
Three Months EndedJune 30, 2020 |
|
Three Months EndedMarch 31, 2020 |
Net loss |
$ |
(9,308 |
) |
|
$ |
(15,898 |
) |
Income tax expense |
|
1,017 |
|
|
|
1,348 |
|
Interest expense (income), net |
|
3,397 |
|
|
|
2,875 |
|
Depreciation and amortization (1) |
|
1,089 |
|
|
|
1,050 |
|
EBITDA (Non-IFRS) |
$ |
(3,805 |
) |
|
$ |
(10,625 |
) |
Non-cash share-based compensation |
|
1,211 |
|
|
|
1,319 |
|
Fair value adjustments on sale of inventory and on biological
assets |
|
(35 |
) |
|
|
(73 |
) |
Fair value changes in derivative warrants |
|
3,748 |
|
|
|
(2,587 |
) |
Net gain on business combination |
|
- |
|
|
|
(2,202 |
) |
Losses (gains) on investments and financial assets |
|
(2,332 |
) |
|
|
8,210 |
|
Pre-acquisition expense |
|
- |
|
|
|
- |
|
Adjusted EBITDA (Non-IFRS) |
$ |
(1,213 |
) |
|
$ |
(5,959 |
) |
|
|
|
|
(1) Includes depreciation included in cost of goods
sold |
|
|
|
|
Jushi (CSE:JUSH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Jushi (CSE:JUSH)
Historical Stock Chart
From Dec 2023 to Dec 2024